To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Impact
If passed, HB 679 would directly impact the legal framework surrounding abortion medications, particularly mifepristone. This would involve the nullification of any modifications to the REMS currently in place that govern how this medication is prescribed and distributed. Critics of the bill argue that it could restrict access to safe and legal abortion care by imposing undue burdens on healthcare providers and patients, straying further from a patient's right to choose. The bill's enactment could lead to a reevaluation of state healthcare laws concerning abortion access and legislation surrounding women's reproductive health.
Summary
House Bill 679 seeks to nullify recent modifications made by the Food and Drug Administration (FDA) in January 2023 to the risk evaluation and mitigation strategy (REMS) for the abortion pill mifepristone. The core aim of the bill is to reinstate previous regulations regarding the distribution and use of mifepristone, particularly its availability and safety measures required for its administration. Proponents of the bill assert that recent FDA changes compromise patient safety and could lead to increased risk in the use of the medication, suggesting that stricter controls are necessary to ensure the pill’s proper administration.
Contention
The introduction of HB 679 has sparked significant debate among legislators and advocacy groups. Supporters emphasize the need for stricter regulations to protect women’s health, asserting that the recent changes by the FDA were made without adequate consideration of potential health risks. Conversely, opponents raise concerns that the bill represents an attempt to undermine access to abortion services and limit women's autonomy over their reproductive choices, which they argue runs counter to established legal precedents. The bill's potential to restrict access to mifepristone will undoubtedly continue to be at the forefront of contentious discussions surrounding abortion rights in the U.S.
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
A bill for an act relating to abortions including definitions, informed consent, dispensing of abortion-inducing drugs, and other abortion-related provisions. (Formerly HF 2563, HSB 704.) Effective date: 07/01/2026.
To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes.
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.(Formerly HSB 704; See HF 2788.)